ES2909835T3 - Métodos para determinar y alcanzar dosis terapéuticamente efectivas de agentes anti-CD47 en el tratamiento del cáncer - Google Patents

Métodos para determinar y alcanzar dosis terapéuticamente efectivas de agentes anti-CD47 en el tratamiento del cáncer Download PDF

Info

Publication number
ES2909835T3
ES2909835T3 ES17783254T ES17783254T ES2909835T3 ES 2909835 T3 ES2909835 T3 ES 2909835T3 ES 17783254 T ES17783254 T ES 17783254T ES 17783254 T ES17783254 T ES 17783254T ES 2909835 T3 ES2909835 T3 ES 2909835T3
Authority
ES
Spain
Prior art keywords
dose
agent
antibody
therapeutically effective
hu5f9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17783254T
Other languages
English (en)
Spanish (es)
Inventor
Irving L Weissman
Mark P Chao
Ravindra Majeti
Jie Liu
Jens-Peter Volkmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2909835T3 publication Critical patent/ES2909835T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17783254T 2016-04-15 2017-04-14 Métodos para determinar y alcanzar dosis terapéuticamente efectivas de agentes anti-CD47 en el tratamiento del cáncer Active ES2909835T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US201662427679P 2016-11-29 2016-11-29
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Publications (1)

Publication Number Publication Date
ES2909835T3 true ES2909835T3 (es) 2022-05-10

Family

ID=60042716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17783254T Active ES2909835T3 (es) 2016-04-15 2017-04-14 Métodos para determinar y alcanzar dosis terapéuticamente efectivas de agentes anti-CD47 en el tratamiento del cáncer

Country Status (12)

Country Link
US (3) US11472878B2 (enExample)
EP (3) EP3442578B1 (enExample)
JP (3) JP7532009B2 (enExample)
KR (3) KR20240016445A (enExample)
CN (3) CN117695387A (enExample)
AU (2) AU2017250809B2 (enExample)
CA (1) CA3019676A1 (enExample)
ES (1) ES2909835T3 (enExample)
PL (1) PL3442578T3 (enExample)
PT (1) PT3442578T (enExample)
SI (1) SI3442578T1 (enExample)
WO (1) WO2017181033A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
PL4177270T3 (pl) 2017-10-18 2024-11-18 Forty Seven, Inc. Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47
EP3752190B1 (en) * 2018-02-12 2022-07-06 Forty Seven, Inc. Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
IL301972A (en) * 2020-10-09 2023-06-01 Sana Biotechnology Inc Methods for activating safe killing mechanisms using the CD47–SIRPα blocking factor
WO2022140659A2 (en) 2020-12-23 2022-06-30 D-10 Therapeutics, Inc. Anti-cd47 antibodies and uses thereof
JP2024503822A (ja) * 2021-01-05 2024-01-29 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
EP2249801A2 (en) * 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
ME03512B (me) 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN105189556A (zh) * 2013-03-15 2015-12-23 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
JP6615745B2 (ja) * 2013-03-27 2019-12-04 ジェネンテック， インコーポレイテッド ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
WO2014179132A1 (en) * 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
AU2015329696A1 (en) * 2014-10-10 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation

Also Published As

Publication number Publication date
EP4349412A3 (en) 2024-06-12
WO2017181033A1 (en) 2017-10-19
SI3442578T1 (sl) 2022-05-31
KR102505253B1 (ko) 2023-03-02
EP3442578A1 (en) 2019-02-20
US20190106491A1 (en) 2019-04-11
JP2019515899A (ja) 2019-06-13
KR20180134367A (ko) 2018-12-18
CA3019676A1 (en) 2017-10-19
CN117695387A (zh) 2024-03-15
AU2017250809A1 (en) 2018-10-25
JP2024059764A (ja) 2024-05-01
US11472878B2 (en) 2022-10-18
KR20240016445A (ko) 2024-02-06
US20230068235A1 (en) 2023-03-02
PL3442578T3 (pl) 2022-06-20
CN109152837A (zh) 2019-01-04
JP2022172278A (ja) 2022-11-15
EP4074339A1 (en) 2022-10-19
US20230406923A1 (en) 2023-12-21
JP7532009B2 (ja) 2024-08-13
PT3442578T (pt) 2022-05-19
AU2024203396A1 (en) 2024-06-06
EP3442578A4 (en) 2019-04-10
CN115350276A (zh) 2022-11-18
US11718670B2 (en) 2023-08-08
KR20230035435A (ko) 2023-03-13
EP3442578B1 (en) 2022-02-09
AU2017250809B2 (en) 2024-02-29
EP4349412A2 (en) 2024-04-10
JP7442591B2 (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
US11718670B2 (en) Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
US20220387314A1 (en) Albumin-pd-1 paclitaxel nanoparticle complex compositions and methods of making and using the same
US20250170067A1 (en) Carrier-Binding Agent Compositions and Methods of Making and Using the Same
US11655301B2 (en) Carrier-binding agent compositions and methods of making and using the same
ES2927305T3 (es) Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
ES2962260T3 (es) Proteínas de fusión SIRPa alfa-anticuerpo
ES2728066T3 (es) Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47
US20220183980A1 (en) Carrier-binding agent compositions and methods of making and using the same
ES2989007T3 (es) Terapia contra el cáncer de ovarios basada en agente anti-CD47
BR112021001691A2 (pt) método de tratamento de câncer de ovário, câncer peritoneal ou câncer de trompa de falópio, e, kit
WO2021041171A1 (en) Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof
EP4314831A2 (en) Tgf-beta inhibitors and use thereof
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40108467A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途